Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “FLT3-mutated Acute Myeloid Leukemia”

90 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 90 results

Testing effectiveness (Phase 2)Ended earlyNCT02634827
What this trial is testing

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With Gene MutationsFLT3 Tyrosine Kinase Domain Point Mutation+2 more
Mayo Clinic 1
Not applicableStudy completedNCT05193448
What this trial is testing

A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE

Who this might be right for
Refractory AMLRelapsed Adult AMLFLT3-TKD Mutation+1 more
French Innovative Leukemia Organisation 177
Large-scale testing (Phase 3)UnknownNCT03258931
What this trial is testing

Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Who this might be right for
Newly Diagnosed FLT3 Mutated AML
Arog Pharmaceuticals, Inc. 510
Testing effectiveness (Phase 2)Study completedNCT00030186
What this trial is testing

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

Who this might be right for
Leukemia, Myeloid
Cephalon 37
Testing effectiveness (Phase 2)Study completedNCT01892371
What this trial is testing

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
FLT3 Gene Mutation NegativeFLT3 Internal Tandem Duplication PositiveRecurrent Acute Myeloid Leukemia+5 more
M.D. Anderson Cancer Center 73
Large-scale testing (Phase 3)Study completedNCT02421939
What this trial is testing

ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Who this might be right for
Leukemia, Acute Myeloid (AML)
Astellas Pharma Global Development, Inc. 371
Testing effectiveness (Phase 2)Study completedNCT00045942
What this trial is testing

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndromes
Novartis Pharmaceuticals 144
Testing effectiveness (Phase 2)Study completedNCT03622541
What this trial is testing

Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3-ITD

Who this might be right for
FLT3-ITD MutationAML
The University of Hong Kong 46
Early research (Phase 1)Looking for participantsNCT05546580
What this trial is testing

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Who this might be right for
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Oryzon Genomics S.A. 50
Large-scale testing (Phase 3)Study completedNCT03379727
What this trial is testing

Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 301
Early research (Phase 1)Ended earlyNCT03552029
What this trial is testing

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Daiichi Sankyo 10
Early research (Phase 1)Looking for participantsNCT06366789
What this trial is testing

Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
AML With Gene Mutations
Lomond Therapeutics Holdings, Inc. 150
Large-scale testing (Phase 3)Not Yet RecruitingNCT05876832
What this trial is testing

XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

Who this might be right for
Acute Myeloid Leukemia With FLT3/ITD Mutation
Shijiazhuang Yiling Pharmaceutical Co. Ltd 312
Not applicableNo Longer AvailableNCT03746912
What this trial is testing

Expanded Treatment Protocol for Adults With FLT3-ITD Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) to Receive Quizartinib

Who this might be right for
Acute Myeloid Leukemia With Gene Mutations
Daiichi Sankyo
Testing effectiveness (Phase 2)Ended earlyNCT01028716
What this trial is testing

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Who this might be right for
Acute Biphenotypic LeukemiaAcute Erythroid Leukemia in RemissionAcute Leukemia in Remission+27 more
Fred Hutchinson Cancer Center 46
Testing effectiveness (Phase 2)Study completedNCT02530476
What this trial is testing

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Who this might be right for
LeukemiaAcute Myeloid Leukemia
M.D. Anderson Cancer Center 17
Testing effectiveness (Phase 2)Looking for participantsNCT04278768
What this trial is testing

Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Who this might be right for
Acute Myelogenous LeukemiaMyelodysplastic Syndrome
Curis, Inc. 366
Large-scale testing (Phase 3)UnknownNCT03642236
What this trial is testing

Combination of BTK Inhibitor Overcomes Drug-resistance in Refractory/Relapsed FLT3 Mutant AML

Who this might be right for
FLT3-ITD MutationAcute Myeloid LeukemiaBrutons Tyrosine Kinase
Nanfang Hospital, Southern Medical University 122
Testing effectiveness (Phase 2)Study completedNCT02927262
What this trial is testing

ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Who this might be right for
Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
Astellas Pharma Global Development, Inc. 98
Testing effectiveness (Phase 2)Study completedNCT01883362
What this trial is testing

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 60
Load More Results